Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication

Bruce Arroll MBChB, PhD, FRNZCGP; Henry Wallace

ABSTRACT

INTRODUCTION: Thiazide diuretics are commonly prescribed in the treatment of hypertension. However, thiazide diuretics may not all be equal in their ability to reduce cardiovascular disease outcomes.

AIM: To determine if bendroflumethiazide/bendrofluazide, the most commonly used diuretic for hypertension in New Zealand, is as effective as other diuretics in terms of cardiovascular disease outcomes.

METHODS: Using recent reviews of thiazide-like (chlorthalidone or indapamide) and thiazide-type diuretics (hydrochlorothiazide and bendrofluazide) and a separate search of bendrofluazide, data on cardiovascular disease outcomes was extracted.

RESULTS: Nineteen relevant papers with 21 comparisons were found. All thiazide-based diuretics have been reported in at least one trial showing them to be more effective than placebo for cardiovascular disease outcomes, with the exception of chlorothiazide. There were no comparisons of bendrofluazide alone with other medications, but there were two studies with either bendrofluazide or hydrochlorothiazide compared with β-blockers; however, the pooled relative risk (RR) was not significant (RR = 1.10 (95% CI, 0.84–1.43)). For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically significant for cardiovascular disease outcomes (RR = 0.91 (95% CI, 0.85–0.98)). Chlorthalidone was significantly more effective for some cardiovascular disease outcomes when compared with doxazosin, amlodipine and lisinopril.

CONCLUSIONS: All thiazide-based medicines available in New Zealand are effective in terms of cardiovascular disease outcomes compared with placebo when used for treating hypertension, with the exception of chlorothiazide. Of the diuretics available in New Zealand for hypertension, only chlorthalidone has been shown to be more effective than other blood pressure-lowering medicines. It may be time to change from using bendrofluazide and start using chlorthalidone as a treatment for hypertension.

KEYWORDS: Thiazides; diuretics; hypertension; cardiovascular diseases

Introduction

Thiazide diuretics are recommended as first-line therapy for hypertension in New Zealand and are among the most commonly prescribed drugs worldwide.1,2 However, not all thiazide diuretics are equal in their ability to reduce cardiovascular disease outcomes.3,4 According to their molecular structure, thiazide diuretics can be divided in thiazide-type and thiazide-like diuretics.

Department of General Practice and Primary Health Care, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Drugs with a similar pharmacologic action on the kidney that do not have the thiazide chemical structure, such as indapamide, chlorthalidone and metolazone, are termed ‘thiazide-like diuretics’.5 Thiazide-like diuretics have a longer elimination half-life than thiazide-type diuretics, and have been shown to exert additional pharmacological effects, which may differently affect cardiovascular risk.4

Thiazide-type diuretics include bendrofluazide, chlorthalidone and hydrochlorothiazide. Bendrofluazide is the most commonly used thiazide diuretic for hypertension in New Zealand, representing ~88% of the market (PHARMAC, pers. comm. to B. Arroll 2015). Chlorthalidone 7%, indapamide 5% and chlorothiazide 0.03% are the other thiazide diuretics available in New Zealand, but chlorothiazide is available only in a liquid form in the New Zealand market (PHARMAC, pers. comm. to B. Arroll 2015). Despite being a commonly prescribed medication, there is limited evidence on the ability of bendrofluazide to lower blood pressure. A Cochrane review found only one trial investigating blood pressure lowering by bendrofluazide, compared with eight trials for chlorthalidone, 40 trials for hydrochlorothiazide and 10 trials for indapamide.5

The most commonly used anti-hypertensive in the United States is hydrochlorothiazide, but it is only available in combination with an angiotensin-converting enzyme (ACE) or angiotensin receptor blocker (ARB) medication in New Zealand. There has been debate in the literature over the dose of hydrochlorothiazide, which seems to have a dose-dependent blood pressure-lowering effect that does not occur with other diuretics. As a result of its dose-dependent response, as well as its ‘paltry’ antihypertensive efficacy and poor adherence, there has been a challenge to the use of hydrochlorothiazide in the USA and it has been suggested that chlorthalidone be used in its place.6 Additionally, according to current United Kingdom National Institute of Health and Clinical Excellence (NICE) guidelines, ‘If diuretic treatment is to be initiated or changed, offer a thiazide-like diuretic, such as chlorthalidone or indapamide, in preference to a conventional thiazide diuretic such as bendroflumethiazide or hydrochlorothiazide.’7 These international recommendations for the use of thiazide-like diuretics instead of thiazide-type diuretics raise the issue of how bendrofluazide, the New Zealand hydrochlorothiazide equivalent, compares with other diuretics such as chlorthalidone and indapamide. There is no single review considering the New Zealand context where only four types of thiazide diuretic are available. New Zealand has the second highest stroke rate in the developed world and we speculate that this may, in part, be due to using a relatively ineffective diuretic.8

Methods
We have taken two recent systematic reviews of thiazide-like and thiazide-type diuretics, published in 2015,6,8 and assumed that these reviews contain all relevant studies published before 2015. We then performed a follow-up systematic search for relevant papers published during the remainder of 2015. We have also conducted a literature search on bendrofluazide, which was not included in the searches of the 2015 reviews, for studies reporting cardiovascular disease or mortality outcomes.

The search was conducted on 26 November 2015 and covered the Cochrane Central Register of Controlled Trials [CENTRAL] (all years to date), MEDLINE (1950-present), Embase (1980-present), and PubMed (1966-present). The reference lists of included studies were also scanned for any additional and relevant studies. We wished to examine all randomised placebo controlled trials (RCT) using thiazide-like (chlorthalidone and
indapamide) and thiazide-type (bendrofluazide, hydrochlorothiazide and chlorothiazide) diuretics as an intervention for hypertension, with results reported in terms of cardiovascular disease outcomes. We chose combined cardiovascular disease outcomes, rather than cardiovascular mortality, as we are aware that some research was underpowered to detect a difference in mortality and hence wished to use an outcome that was likely to be common to all studies.

The data from identified papers were extracted in duplicate by HW and BA, including the PICOs (participants, interventions, comparison and outcomes) information, as shown in Table 1. Risk of bias was assessed using the Cochrane Collaboration tool for assessing the risk of bias (Table 8.5.a in the Cochrane Handbook for Systematic Reviews of Interventions, http://handbook.cochrane.org/). Summary measures were the relative risk and confidence intervals and data were pooled where possible using the Cochrane RevMan software (version 5.3.5, The Cochrane Collaboration, Copenhagen, Denmark). All analyses, unless otherwise specified, used a random effects model as the most conservative option.

Results

We found 19 papers with 21 comparisons that met our selection criteria (see flow chart Figure 1). All but one reported multiple cardiovascular outcomes, and for these studies, we have reported combined cardiovascular disease outcomes.9 For the remaining study, we have reported only cardiovascular disease mortality.

There were three papers reporting bendrofluazide5–11 outcomes, two papers using chlorothiazide12,13 five papers reporting five outcomes for chlorthalidone,14–18 10 papers using hydrochlorothiazide19–26 and one paper reporting on indapamide reporting the medication to be more effective than placebo in terms of reducing cardiovascular events, other than chlorothiazide.

Chlorothiazide

The pooled data for chlorothiazide versus placebo was not statistically significant (RR = 0.82 (95% CI, 0.66–1.01)). There were no studies involving chlorothiazide versus other medications.

Chlorthalidone

The only diuretic available in New Zealand to show a statistically significant benefit compared with multiple medications was chlorthalidone. There were two studies comparing chlorthalidone with placebo and the summary relative risk was statistically significant (RR = 0.68 (95% CI, 0.58–0.80)).16,17 Compared with chlorthalidone, doxazosin was associated with more combined cardiovascular disease adverse outcomes (RR = 1.25 (95% CI, 1.17–1.33)), as well as congestive heart failure (RR = 2.04 (95% CI, 1.79–2.32)) and stroke (RR = 1.19 (95% CI, 1.01–1.40)).15 Similarly, compared with chlorthalidone, lisinopril was associated with more combined cardiovascular disease adverse outcomes (RR = 1.10 (95% CI, 1.05–1.16)), stroke (RR = 1.15 (95% CI, 1.02–1.30)) and heart failure (RR = 1.19 (95% CI, 1.07–1.31)).15 Also, compared with chlorthalidone, amlodipine had a higher incidence of heart failure (RR = 1.38 (95% CI, 1.25–1.52)) and combined cardiovascular disease outcomes (RR = 1.04 (95% CI, 0.99–1.09)).15 Overall, for chlorthalidone, there were four comparisons versus other medications, and the summary relative risk was statistically significant for cardiovascular disease outcomes (RR = 0.91 (95% CI, 0.85–0.98; Figure 2)). There was no comparison where doxazosin, amlodipine and lisinopril were more effective than chlorthalidone.

Indapamide

There was only one study involving indapamide.27 It was found to be significantly better than placebo for combined cardiovascular disease outcomes (RR = 0.71 (95% CI, 0.574–0.872)).27 There were no studies comparing indapamide with other medications.
Table 1. Characteristics of randomised placebo-controlled trials and cardiovascular disease outcomes for four anti-hypertensive thiazide-like diuretics available in New Zealand

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Total Participants (n)</th>
<th>Treatment (drug)</th>
<th>Dose (mg)</th>
<th>Participants using Diuretic (%)</th>
<th>Participants on Control or Other (%)</th>
<th>Funding</th>
<th>Mean Follow Up (years)</th>
<th>CVD RR</th>
<th>95% CI</th>
<th>Summary of CVD outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bendrofluazide vs. Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BDFZ &gt; placebo</td>
</tr>
<tr>
<td>MRC I (1985) [7]</td>
<td>4297/8654</td>
<td>Bendrofluazide</td>
<td>Placebo</td>
<td>10.00</td>
<td>N/A</td>
<td>PF + IF</td>
<td>5.00</td>
<td>0.80</td>
<td>0.66–0.97</td>
<td></td>
</tr>
<tr>
<td>Chlorothiazide vs. Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chlorothiazide = placebo</td>
</tr>
<tr>
<td>ANBP (1980) [9]</td>
<td>1721/1706</td>
<td>Chlorothiazide</td>
<td>Placebo</td>
<td>500.00–1000.00</td>
<td>N/A</td>
<td>PF</td>
<td>4.04</td>
<td>0.81</td>
<td>0.66–1.01</td>
<td></td>
</tr>
<tr>
<td>PHSH (1977) [10]</td>
<td>193/196</td>
<td>Chlorothiazide + Rauwolfiaserpenita</td>
<td>Placebo</td>
<td>500.00</td>
<td>N/A</td>
<td>PF</td>
<td>7.00</td>
<td>0.90</td>
<td>0.36–2.30</td>
<td></td>
</tr>
<tr>
<td>Chlorthalidone vs. Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CTDN &gt; placebo</td>
</tr>
<tr>
<td>SHEP-PS (1989) [13]</td>
<td>443/108</td>
<td>CTDN</td>
<td>Placebo</td>
<td>25.00</td>
<td>N/A</td>
<td>PF</td>
<td>2.59</td>
<td>0.54</td>
<td>0.33–0.87</td>
<td></td>
</tr>
<tr>
<td>SHEP (1991) [14]</td>
<td>2365/2371</td>
<td>CTDN</td>
<td>Placebo</td>
<td>12.50–25.00</td>
<td>N/A</td>
<td>AT 5 years: 21.00% other antihypertensives 9.00% no antihypertensives</td>
<td>PF + IF</td>
<td>4.68</td>
<td>0.70</td>
<td>CTDN &gt; placebo</td>
</tr>
<tr>
<td>Chlorthalidone vs. Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CTDN = amlodipine</td>
</tr>
<tr>
<td>ALLHAT D (2000) [12]</td>
<td>15268/9067</td>
<td>CTDN</td>
<td>Doxazosin</td>
<td>12.50–25.00</td>
<td>2.00–8.00</td>
<td>62.70</td>
<td>37.30</td>
<td>PF + IF</td>
<td>2.91</td>
<td>0.83</td>
</tr>
<tr>
<td>ALLHAT L (2002) [11]</td>
<td>15255/9054</td>
<td>CTDN</td>
<td>Lisinopril</td>
<td>12.00</td>
<td>10.00–40.00</td>
<td>62.80</td>
<td>37.20</td>
<td>PF + IF</td>
<td>4.90</td>
<td>0.93</td>
</tr>
<tr>
<td>SHELL (2003) [15]</td>
<td>940/942</td>
<td>CTDN</td>
<td>Lacidipine</td>
<td>12.50–25.00</td>
<td>4.00</td>
<td>49.90</td>
<td>50.10</td>
<td>IF</td>
<td>2.67</td>
<td>0.98</td>
</tr>
<tr>
<td>High Dose Hydrochlorothiazide vs. Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HCTZ (100mg) &gt; placebo</td>
</tr>
<tr>
<td>VA I (1967) [21]</td>
<td>73/70</td>
<td>HCTZ + Reserpine + Hydralazine hydrochloride</td>
<td>Placebo</td>
<td>100.00</td>
<td>N/A</td>
<td>?</td>
<td>1.52</td>
<td>0.07</td>
<td>0.02–0.29</td>
<td></td>
</tr>
<tr>
<td>VA II (1970) [22]</td>
<td>186/194</td>
<td>HCTZ + Reserpine + Hydralazine hydrochloride</td>
<td>Placebo</td>
<td>500.00–150.00</td>
<td>N/A</td>
<td>PF + IF</td>
<td>4.78</td>
<td>0.41</td>
<td>0.26–0.64</td>
<td></td>
</tr>
<tr>
<td>Low Dose Hydrochlorothiazide vs. Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HCTZ + Triamterene &gt; placebo</td>
</tr>
<tr>
<td>EWPHE (1985) [16]</td>
<td>416/424</td>
<td>HCTZ + Triamterene</td>
<td>Placebo</td>
<td>25.00–50.00</td>
<td>N/A</td>
<td>PF + IF</td>
<td>3.89</td>
<td>0.63</td>
<td>0.46–0.86</td>
<td></td>
</tr>
</tbody>
</table>
### Table 1. (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Duration</th>
<th>Follow-up</th>
<th>Primary Outcome</th>
<th>Relative Risk</th>
<th>95% CI</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANBP II (2003) [23]</td>
<td>3039-3044</td>
<td>HCTZ vs. Enalapril</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HCTZ = enalapril</td>
</tr>
<tr>
<td>INSIGHT (2000) [18]</td>
<td>3164-3157</td>
<td>HCTZ + Amiloride vs. Nifedipine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HCTZ + Amiloride &gt;</td>
</tr>
<tr>
<td>MIDAS (1996) [17]</td>
<td>441-442</td>
<td>HCTZ vs. Isradipine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HCTZ = Isradipine (CCB)</td>
</tr>
</tbody>
</table>

* = outcomes for MAPHY study are mortality not cardiovascular outcomes.

KEY: ?, unknown; >, superior to; <, inferior to; =, equal to; >=, equal or superior to; I, one; II, two; A, Amlodipine arm; ACCOMPLISH, Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP, Australian National Blood Pressure study; CCB, calcium channel blocker; CI, confidence interval; CTDN, Chlorthalidone; CVD, cardiovascular disease; D, Doxazosin arm; EWPHE, European Working Party on High Blood Pressure in the Elderly trial; HAPPHY, Heart Attack Primary Prevention in Hypertension trial; HCTZ, hydrochlorothiazide; HYVET, Hypertension in the Very Elderly Trial; IF, industrial funding; INSIGHT, International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment; L, Lisinopril arm; MAPHY, Metoprolol in Patients with Hypertension; MIDAS, Multicenter Isradipine Diuretic Atherosclerosis Study; MRC I, Medical Research Council Working Party; N/A, not applicable; P, placebo arm; PF, public funding; PS, pilot study; SHELL, Systolic Hypertension in the Elderly: Lacidipine Long-Term study; SHEP, Systolic Hypertension in the Elderly Program; VA, Veterans Administration Cooperative Study Group on Antihypertensive Agents; RR, relative risk.
Bendrofluazide/Hydrochlorothiazide

The two low-dose hydrochlorothiazide studies identified used hydrochlorothiazide concurrently with amiloride or triamterene and hence are not a pure comparison. Both were effective when compared with placebo in terms of reducing cardiovascular disease outcomes and the pooled relative risk (RR = 0.68 (95% CI 0.57 – 0.81)) was also significant. Two other studies compared bendrofluazide or hydrochlorothiazide and neither was more effective than β-blocker(s) with the pooled relative risk (RR = 1.10 (95% CI, 0.84 – 1.43)). There were two papers reporting that a high dose of hydrochlorothiazide (100 mg per day) was significantly more effective than placebo (VA I and VA II) (Veterans Administration Cooperative Study Group on Antihypertensive Agents). As the data came from the same study, we used a fixed-effects analysis and the pooled relative risk (RR = 0.3 (95% CI, 0.19 – 0.45)). When hydrochlorothiazide was compared with other medications, the pooled relative risk (RR = 0.99 (95% CI, 0.86 – 1.15)) was not significant. There were no comparisons of bendrofluazide/bendrofluazide alone with other medications.

Risk of bias

The risk of bias (using the Cochrane Collaboration system) was low for the significant chlorthalidone studies; that is ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), main SHEP (Systolic Hypertension in the Elderly Program) and the indapamide study (HYVET). For the bendrofluazide versus placebo study, there was a high risk of bias, as the medication and study personnel were not blinded. The two chlorothiazide studies were at low risk of bias.

Discussion

Other than chlorothiazide, there was at least one study for each of the thiazide diuretics used to treat hypertension in New Zealand (bendrofluazide, chlorthalidone, indapamide, chlorothiazide) reporting the medication to be more effective than placebo in terms of reducing cardiovascular events.

Of those four thiazide diuretics, the only one that was significantly more effective than other medications was chlorthalidone. It was more effective than lisinopril, amloidipine and doxazosin for several cardiovascular disease outcomes. Furthermore, there were no analyses where doxazosin, amloidipine or lisinopril was more effective than chlorthalidone.

Bendrofluazide has not been compared against other anti-hypertensive medications, but was superior to placebo in one study (MRC I) for combined cardiovascular disease events. It was effective for stroke but not coronary heart events. The study was unblinded and hence at high risk of bias. In both the SHEP pilot and main SHEP
trial, using chlorthalidone was significantly more effective than placebo. On balance, we feel that there is more evidence for using chlorthalidone than bendrofluazide, and that New Zealand-based clinicians should consider this evidence when choosing a thiazide diuretic for treating hypertension.

In terms of side-effect profiles, a recent review was unable to draw conclusions about the prevalence of thiazide-induced hyponatremia with respect to individual thiazide medications. Another review reported that when compared to other antihypertensive therapy, both thiazide-like and thiazide-type diuretics showed a similar number of adverse events in patients with comparable reductions in blood pressure.

**Strengths and limitations**

While hydrochlorothiazide is the most commonly prescribed thiazide diuretic worldwide, we have not focused on it, as it is not available in New Zealand as a stand-alone medicine. We concur with other critics that the usual dose of 25–50 mg is not supported by evidence and that if it is used alone, then doses of 100 mg need to be considered. We considered combined cardiovascular disease outcomes as our primary outcome as this was likely to be reported in most papers. There was only one paper that did not report this, but reported cardiovascular disease mortality as the outcome. We acknowledge that using the cardiovascular disease composite outcomes could have led to overstatement of the benefits of the drugs in each of the studies we used, and that the use of non-uniform composite outcomes could also bias results towards studies with a broad criteria of a cardiovascular disease outcome.

**Other literature**

A recent review of thiazide diuretics concluded that ‘preferential use of thiazide-like diuretics over thiazide-type diuretics may result in greater cardiovascular disease benefits in hypertensive patients’ and suggested that ‘the use of thiazide diuretics in hypertensive patients results in a reduction in the risk of cardiovascular disease outcomes’. Moreover, thiazide-like diuretics have a greater protective effect against cardiovascular disease outcomes than thiazide-type diuretics, especially with regard to heart failure, suggesting that preferential use of thiazide-like diuretics over thiazide-type diuretics may result in greater cardiovascular benefits in hypertensive patients. Another review reported that thiazide-like diuretics resulted in a 12% additional risk reduction when compared with thiazide-type diuretics for cardiovascular disease events, and an additional 21% risk reduction for heart failure. There has been debate over the blood pressure-lowering ability of these medications, but our view is that cardiovascular disease outcomes are the gold standard when looking at effectiveness. Blood pressure lowering is a surrogate outcome.

There is also a suggestion that some of chlorthalidone’s effectiveness is due to its effect on other processes and longer duration of action. Additionally, the fact that there was only a 2-mmHg difference between chlorthalidone and lisinopril in the ALLHAT trial is because the former had more patients reach the target blood pressure. An editorial on the ALLHAT trial also suggested there were issues of a certain number of patients getting drug classes from other treatment arms, and that an on-treatment analysis would be welcome, although Fagard conceded that the intention-to-treat analysis was the most conservative and appropriate. Another editorial accompanying the Rik et al. (2015) review favoured either indapamide or chlorthalidone. While it concluded that indapamide had some better features (e.g. cost, availability and formulation), none of these are issues in New Zealand. Considering the available evidence, our view is that chlorthalidone is the more effective medication for hypertension in terms of cardiovascular disease outcomes.

Figure 2: Pooled studies of chlorthalidone versus other medications in terms of cardiovascular disease outcomes. ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) A 2002, chlorthalidone vs. amlodipine; ALLHAT D 2000, chlorthalidone vs. doxazosin; ALLHAT L 2002, chlorthalidone vs. lisinopril

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Chlorthalidone Events</th>
<th>Total</th>
<th>Other Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
<th>M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLHAT A 2002</td>
<td>1941</td>
<td>15255</td>
<td></td>
<td>2412</td>
<td>9048</td>
<td>32.6%</td>
<td>0.96 (0.92, 1.00)</td>
<td></td>
</tr>
<tr>
<td>ALLHAT D 2000</td>
<td>2245</td>
<td>15256</td>
<td></td>
<td>1592</td>
<td>5067</td>
<td>29.4%</td>
<td>0.84 (0.79, 0.89)</td>
<td></td>
</tr>
<tr>
<td>ALLHAT L 2002</td>
<td>1941</td>
<td>15255</td>
<td>2514</td>
<td>5054</td>
<td>32.8%</td>
<td>0.93 (0.89, 0.87)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHELL 2003</td>
<td>1941</td>
<td>15255</td>
<td>902</td>
<td>942</td>
<td>5.2%</td>
<td>0.98 (0.74, 1.30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>46718</td>
<td>28111</td>
<td></td>
<td>10125</td>
<td>6428</td>
<td>100.0%</td>
<td>0.91 (0.85, 0.98)</td>
<td></td>
</tr>
</tbody>
</table>

Test for overall effect: X² = 2.57 (P = 0.11)
Implications for research

We were surprised at the low number of trials for bendrofluazide, chlorthalidone and indapamide in comparison with hydrochlorothiazide. A definitive trial of chlorthalidone versus hydrochlorothiazide and bendrofluazide would be informative, but would require a large sample size of the order of the ALLHAT trial, which included 33,357 participants. None of these medications are covered by a patent, so there is not likely to be an industry-funded trial.

Implications for practice

Our view is that there is more evidence supporting chlorthalidone as the first choice of diuretic compared with bendrofluazide or indapamide. All three are fully funded in New Zealand. We feel it is time for clinicians to consider switching from bendrofluazide to chlorthalidone.

References

Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143–52. doi:10.1001/jama.1970.03170330025003

COMPETING INTERESTS
None.

FUNDING
Henry Wallace received a Summer Research Scholarship from the Royal New Zealand College of General Practitioners (RNZCGP). The RNZCGP is not involved in any other aspect of the project, such as the design of the project's protocol and analysis plan, the collection, analyses or decision to publish.